Breaking Finance News

MacroGenics Inc (NASDAQ:MGNX) target price raised to $33.00, issued a report today by Zacks Investment Research

MacroGenics Inc (NASDAQ:MGNX) had its target bumped up to $33.00 by Zacks Investment Research in an issued report announced 10/12/2016. The new target price indicates a potential upside of 0.12% from the company's last closing price.

Yesterday MacroGenics Inc (NASDAQ:MGNX) traded -4.92% lower at $29.51. The company’s 50-day moving average is $29.84 and its 200-day moving average is $26.15. The last closing price is up -3.94% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 362,282 shares of the stock traded hands, up from an average trading volume of 219,508

See Chart Below

MacroGenics Inc (NASDAQ:MGNX)

MacroGenics Inc has a 52 week low of $14.84 and a 52 week high of $36.11 The company’s market cap is currently $0.

General Information About MacroGenics Inc (NASDAQ:MGNX)

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *